首页 > 最新文献

Journal of Clinical Hypertension最新文献

英文 中文
Mean Platelet Volume and Plateletcrit Values May Not Be Associated With the Severity of Preeclampsia 平均血小板体积和血小板crit值可能与先兆子痫的严重程度无关。
IF 2.7 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-09-30 DOI: 10.1111/jch.14907
Cengiz Beyan
<p>I read with great interest the study by Peng et al. which examined the relationship between coagulation and platelet parameters and pregnancy outcome in patients with preeclampsia [<span>1</span>]. In this study, it was found that platelet count, mean platelet volume (MPV), and plateletcrit (PCT) values were significantly reduced with the severity of preeclampsia, and the researchers argued that their study showed a significant relationship between coagulation and platelet parameters and the severity of preeclampsia and adverse pregnancy outcome. I want to emphasize the existence of some factors that negatively affect the evaluation of platelet parameters in this study.</p><p>Since the measurement of MPV, a platelet parameter, has not yet been standardized, the use of these values for purposes such as diagnosis or prognosis, especially in acquired diseases, is definitely not recommended [<span>2</span>]. The main factors affecting MPV measurement standardization are the type of anticoagulant used in the measurement, the time between blood collection and measurement, and the devices used in the measurement [<span>3-5</span>]. As in this study, the most commonly used anticoagulant in complete blood counts is ethylenediaminetetraacetic acid (EDTA), and when platelets come into contact with EDTA in the blood tube, they undergo rapid growth, change shape, and develop pseudopods [<span>3</span>]. The increase in MPV caused by EDTA contact can be up to 30% in the first 5 min and 40%–45% in the first 2 h [<span>3</span>]. In studies using EDTA as an anticoagulant, increases of 2%–50% in MPV values have been reported [<span>3-5</span>]. Deviations in MPV values have also been reported with other anticoagulants [<span>4, 5</span>]. Differences in the devices used in the measurement can cause deviations of up to 40% in MPV values [<span>5-7</span>]. Since the determination of another platelet parameter, PCT (=platelet count × MPV/10 000), is made by calculation based on MPV values, any factor that negatively affects the measurement of MPV values also negatively affects PCT values. In the study by Peng et al., the time between blood collection and MPV measurement and the devices used in MPV measurement were not specified, thus negatively affecting the reliability of the MPV data and therefore the PCT data of the study. Also, in the study by Peng et al., comparisons were made between pregnants with and without preeclampsia, and the absence of a non-pregnant healthy women group in the comparisons made it difficult to understand whether pregnancy had an effect on the deviations detected in platelet parameters.</p><p>Another issue is that it was stated in the discussion section of the article that the change in platelet parameters reflects the decrease in platelet function. The gold standard test used to measure platelet function is light transmission platelet aggregation in platelet-rich plasma, and studies using this method have shown that there is no corre
我饶有兴趣地阅读了 Peng 等人的研究,该研究探讨了子痫前期患者的凝血和血小板参数与妊娠结局之间的关系[1]。在这项研究中,研究者发现血小板计数、平均血小板体积(MPV)和血小板比容(PCT)值随着子痫前期的严重程度而显著降低,研究者认为他们的研究表明凝血和血小板参数与子痫前期的严重程度和不良妊娠结局之间存在显著的关系。我想强调的是,在这项研究中存在一些对血小板参数评估产生负面影响的因素。由于血小板参数 MPV 的测量尚未标准化,因此绝对不建议将这些数值用于诊断或预后等目的,尤其是后天性疾病[2]。影响 MPV 测量标准化的主要因素包括测量中使用的抗凝剂类型、采血与测量之间的时间间隔以及测量中使用的设备[3-5]。如本研究中,全血细胞计数中最常用的抗凝剂是乙二胺四乙酸(EDTA),当血小板在血管内与 EDTA 接触时,会迅速生长、改变形状并出现假足[3]。接触 EDTA 后,MPV 在最初 5 分钟内可增加 30%,在最初 2 小时内可增加 40%-45% [3]。在使用 EDTA 作为抗凝剂的研究中,有报告称 MPV 值增加了 2%-50%[3-5]。其他抗凝剂也有 MPV 值偏差的报道 [4,5]。测量所用设备的不同可导致 MPV 值出现高达 40% 的偏差 [5-7]。由于另一个血小板参数 PCT(=血小板计数×MPV/10 000)是根据 MPV 值计算得出的,因此任何对 MPV 值测量产生负面影响的因素也会对 PCT 值产生负面影响。在 Peng 等人的研究中,没有明确说明采血与 MPV 测量之间的时间间隔以及测量 MPV 所使用的设备,因此对 MPV 数据的可靠性产生了负面影响,进而影响了该研究的 PCT 数据。此外,在 Peng 等人的研究中,对患有子痫前期和未患有子痫前期的孕妇进行了比较,由于比较中没有非孕期健康妇女组,因此很难了解妊娠是否会对血小板参数的偏差产生影响。用于测量血小板功能的金标准测试是富血小板血浆中的光透射血小板聚集,使用这种方法进行的研究表明,血小板聚集反应与血小板指数(如 MPV 和 PCT)之间没有相关性[8,9]。Cengiz Beyan:构思、设计、材料准备、数据收集、分析、撰写、阅读和最终稿件批准。稿件不包含临床研究或患者数据。
{"title":"Mean Platelet Volume and Plateletcrit Values May Not Be Associated With the Severity of Preeclampsia","authors":"Cengiz Beyan","doi":"10.1111/jch.14907","DOIUrl":"10.1111/jch.14907","url":null,"abstract":"&lt;p&gt;I read with great interest the study by Peng et al. which examined the relationship between coagulation and platelet parameters and pregnancy outcome in patients with preeclampsia [&lt;span&gt;1&lt;/span&gt;]. In this study, it was found that platelet count, mean platelet volume (MPV), and plateletcrit (PCT) values were significantly reduced with the severity of preeclampsia, and the researchers argued that their study showed a significant relationship between coagulation and platelet parameters and the severity of preeclampsia and adverse pregnancy outcome. I want to emphasize the existence of some factors that negatively affect the evaluation of platelet parameters in this study.&lt;/p&gt;&lt;p&gt;Since the measurement of MPV, a platelet parameter, has not yet been standardized, the use of these values for purposes such as diagnosis or prognosis, especially in acquired diseases, is definitely not recommended [&lt;span&gt;2&lt;/span&gt;]. The main factors affecting MPV measurement standardization are the type of anticoagulant used in the measurement, the time between blood collection and measurement, and the devices used in the measurement [&lt;span&gt;3-5&lt;/span&gt;]. As in this study, the most commonly used anticoagulant in complete blood counts is ethylenediaminetetraacetic acid (EDTA), and when platelets come into contact with EDTA in the blood tube, they undergo rapid growth, change shape, and develop pseudopods [&lt;span&gt;3&lt;/span&gt;]. The increase in MPV caused by EDTA contact can be up to 30% in the first 5 min and 40%–45% in the first 2 h [&lt;span&gt;3&lt;/span&gt;]. In studies using EDTA as an anticoagulant, increases of 2%–50% in MPV values have been reported [&lt;span&gt;3-5&lt;/span&gt;]. Deviations in MPV values have also been reported with other anticoagulants [&lt;span&gt;4, 5&lt;/span&gt;]. Differences in the devices used in the measurement can cause deviations of up to 40% in MPV values [&lt;span&gt;5-7&lt;/span&gt;]. Since the determination of another platelet parameter, PCT (=platelet count × MPV/10 000), is made by calculation based on MPV values, any factor that negatively affects the measurement of MPV values also negatively affects PCT values. In the study by Peng et al., the time between blood collection and MPV measurement and the devices used in MPV measurement were not specified, thus negatively affecting the reliability of the MPV data and therefore the PCT data of the study. Also, in the study by Peng et al., comparisons were made between pregnants with and without preeclampsia, and the absence of a non-pregnant healthy women group in the comparisons made it difficult to understand whether pregnancy had an effect on the deviations detected in platelet parameters.&lt;/p&gt;&lt;p&gt;Another issue is that it was stated in the discussion section of the article that the change in platelet parameters reflects the decrease in platelet function. The gold standard test used to measure platelet function is light transmission platelet aggregation in platelet-rich plasma, and studies using this method have shown that there is no corre","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11466356/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multiple factors are related to the development of exaggerated blood pressure response to exercise. 运动时血压反应过高与多种因素有关。
IF 2.7 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-09-30 DOI: 10.1111/jch.14899
Ali Çoner, Can Ramazan Öncel, Cemal Köseoğlu, Göksel Dağaşan
{"title":"Multiple factors are related to the development of exaggerated blood pressure response to exercise.","authors":"Ali Çoner, Can Ramazan Öncel, Cemal Köseoğlu, Göksel Dağaşan","doi":"10.1111/jch.14899","DOIUrl":"https://doi.org/10.1111/jch.14899","url":null,"abstract":"","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Retrospective Comparative Study of Mid-Term Outcomes of Atherectomy, Drug-Coating Balloon Angioplasty, and Plain Old Balloon Angioplasty for Isolated Atherosclerotic Popliteal Artery Lesions. 针对孤立性动脉粥样硬化性腘动脉病变的粥样斑块切除术、药物涂层球囊血管成形术和普通球囊血管成形术中期疗效的回顾性比较研究。
IF 2.7 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-09-28 DOI: 10.1111/jch.14908
Zhiyong Dong, Lianrui Guo, Zhu Tong, Shijun Cui, Xixiang Gao, Chengchao Zhang, Jianming Guo, Yongquan Gu

We retrospectively reviewed the clinical data of 217 consecutive Chinese patients with isolated atherosclerotic popliteal artery lesions treated with atherectomy technique, DCB, and plain old balloon angioplasty from August 2017 to August 2022. There was no difference in the 48-month patency rate between the atherectomy, DCB, and POBA groups (65%, 56%, and 51%, respectively; p = 0.3), as well as in adjusted Cox regression. Similarly, no difference was observed in the 48-month clinically driven target lesion revascularization-free (CDTLR-free) rate among the groups (77%, 74%, and 65%; p = 0.34), confirmed by adjusted Cox regression. In the 48 months, a significant difference was observed in amputation-free rates between the atherectomy, DCB, and POBA groups (97%, 91%, and 83%, respectively; p < 0.05). Adjusted Cox regression indicated POBA had worse outcomes than DCB and atherectomy. In the stenosis and occlusion subgroup, the 48-month primary patency rates were 65%, 70%, and 54% (p > 0.9) and 65% versus 49% versus 49% (p = 0.3), showing no differences among the three groups. In the short lesion subgroup (<10 cm), the 48-month primary patency rates were 65%, 66%, and 61% for atherectomy, DCB, and POBA, respectively (p = 0.7). In the long lesion subgroup (≥10 cm), the 48-month patency rates were higher in the atherectomy and DCB groups compared to POBA (64%, 44%, and 34%), with no significant difference among the groups (p = 0.13). DCB and atherectomy demonstrate improved short- and mid-term clinical outcomes compared to POBA in Chinese patients with popliteal artery disease.

我们回顾性研究了2017年8月至2022年8月期间连续217例中国孤立性动脉粥样硬化腘动脉病变患者的临床数据,这些患者分别接受了动脉粥样硬化切除术、DCB和普通球囊血管成形术治疗。在48个月的通畅率方面,动脉粥样硬化切除术组、DCB组和POBA组之间没有差异(分别为65%、56%和51%;P = 0.3),调整后的Cox回归也没有差异。同样,48 个月无临床驱动靶病变血运重建率(CDTLR-free)在各组之间也未观察到差异(77%、74% 和 65%;P = 0.34),调整后的 Cox 回归也证实了这一点。在 48 个月内,动脉粥样硬化切除术组、DCB 组和 POBA 组的无截肢率(分别为 97%、91% 和 83%;P 0.9)和 65% 对 49% 对 49% 的无截肢率(P = 0.3)之间存在显著差异,表明三组之间无差异。在短病变亚组 (
{"title":"A Retrospective Comparative Study of Mid-Term Outcomes of Atherectomy, Drug-Coating Balloon Angioplasty, and Plain Old Balloon Angioplasty for Isolated Atherosclerotic Popliteal Artery Lesions.","authors":"Zhiyong Dong, Lianrui Guo, Zhu Tong, Shijun Cui, Xixiang Gao, Chengchao Zhang, Jianming Guo, Yongquan Gu","doi":"10.1111/jch.14908","DOIUrl":"https://doi.org/10.1111/jch.14908","url":null,"abstract":"<p><p>We retrospectively reviewed the clinical data of 217 consecutive Chinese patients with isolated atherosclerotic popliteal artery lesions treated with atherectomy technique, DCB, and plain old balloon angioplasty from August 2017 to August 2022. There was no difference in the 48-month patency rate between the atherectomy, DCB, and POBA groups (65%, 56%, and 51%, respectively; p = 0.3), as well as in adjusted Cox regression. Similarly, no difference was observed in the 48-month clinically driven target lesion revascularization-free (CDTLR-free) rate among the groups (77%, 74%, and 65%; p = 0.34), confirmed by adjusted Cox regression. In the 48 months, a significant difference was observed in amputation-free rates between the atherectomy, DCB, and POBA groups (97%, 91%, and 83%, respectively; p < 0.05). Adjusted Cox regression indicated POBA had worse outcomes than DCB and atherectomy. In the stenosis and occlusion subgroup, the 48-month primary patency rates were 65%, 70%, and 54% (p > 0.9) and 65% versus 49% versus 49% (p = 0.3), showing no differences among the three groups. In the short lesion subgroup (<10 cm), the 48-month primary patency rates were 65%, 66%, and 61% for atherectomy, DCB, and POBA, respectively (p = 0.7). In the long lesion subgroup (≥10 cm), the 48-month patency rates were higher in the atherectomy and DCB groups compared to POBA (64%, 44%, and 34%), with no significant difference among the groups (p = 0.13). DCB and atherectomy demonstrate improved short- and mid-term clinical outcomes compared to POBA in Chinese patients with popliteal artery disease.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Joint Modifiable Risk Factor Control and Incident Stroke in Hypertensive Patients. 联合控制可改变的风险因素与高血压患者的卒中发病率。
IF 2.7 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-09-28 DOI: 10.1111/jch.14905
Xuefei Hou, Suru Yue, Zihan Xu, Xiaolin Li, Yingbai Wang, Jia Wang, Xiaoming Chen, Jiayuan Wu

Recent guidelines have recognized several factors, including blood pressure (BP), body mass index (BMI), low-density lipoprotein cholesterol (LDL-C), hemoglobin A1c (HbA1c), smoking, and physical activity, as key contributors to stroke risk. However, the impact of simultaneous management of these risk factors on stroke susceptibility in individuals with hypertension remains ambiguous. This study involved 238 388 participants from the UK Biobank, followed up from their recruitment date until April 1, 2023. Cox proportional hazard models with hazard ratios (HRs) and 95% confidence intervals (CIs) were used to illustrate the correlation between the joint modifiable risk factor control and the stroke risk. As the degree of risk factor control increased, a gradual reduction in stroke risk was observed. Hypertensive patients who had the optimal risk factor control (≥5 risk factor controls) had a 14.6% lower stroke risk than those who controlled 2 or fewer (HR: 0.854; 95% CI: 804-0.908; p < 0.001). The excess risk of stroke linked to hypertension slowly diminished as the number of controlled risk factors increased. However, the risk was still 25.1% higher for hypertensive patients with optimal risk factor control as compared to the non-hypertensive population (HR: 1.251; 95% CI: 1.100-1.422; p < 0.001). The protective effect of joint risk factor control against the stroke risk due to hypertension was stronger in medicated hypertensive patients than in those not medicated. This finding leads to the conclusion that joint risk factor control combined with pharmacological treatment could potentially eliminate the excess risk of stroke associated with hypertension.

最近的指南认为,血压 (BP)、体重指数 (BMI)、低密度脂蛋白胆固醇 (LDL-C)、血红蛋白 A1c (HbA1c)、吸烟和体育锻炼等因素是导致卒中风险的关键因素。然而,同时控制这些风险因素对高血压患者中风易感性的影响仍不明确。这项研究涉及英国生物库中的 238388 名参与者,从他们的招募日期起一直随访到 2023 年 4 月 1 日。研究采用了带有危险比(HRs)和 95% 置信区间(CIs)的 Cox 比例危险模型来说明可改变的危险因素控制与中风风险之间的相关性。随着风险因素控制程度的增加,中风风险逐渐降低。最佳风险因素控制(≥5 个风险因素控制)的高血压患者比控制 2 个或更少风险因素的患者中风风险低 14.6%(HR:0.854;95% CI:804-0.908;P <0.001)。随着受控危险因素数量的增加,与高血压相关的中风超额风险也在慢慢降低。然而,与非高血压人群相比,风险因素得到最佳控制的高血压患者的风险仍高出 25.1%(HR:1.251;95% CI:1.100-1.422;p <0.001)。联合控制风险因素对高血压所致中风风险的保护作用在接受药物治疗的高血压患者中比在未接受药物治疗的患者中更强。这一发现得出的结论是,联合危险因素控制与药物治疗相结合有可能消除与高血压相关的过高中风风险。
{"title":"Joint Modifiable Risk Factor Control and Incident Stroke in Hypertensive Patients.","authors":"Xuefei Hou, Suru Yue, Zihan Xu, Xiaolin Li, Yingbai Wang, Jia Wang, Xiaoming Chen, Jiayuan Wu","doi":"10.1111/jch.14905","DOIUrl":"https://doi.org/10.1111/jch.14905","url":null,"abstract":"<p><p>Recent guidelines have recognized several factors, including blood pressure (BP), body mass index (BMI), low-density lipoprotein cholesterol (LDL-C), hemoglobin A1c (HbA1c), smoking, and physical activity, as key contributors to stroke risk. However, the impact of simultaneous management of these risk factors on stroke susceptibility in individuals with hypertension remains ambiguous. This study involved 238 388 participants from the UK Biobank, followed up from their recruitment date until April 1, 2023. Cox proportional hazard models with hazard ratios (HRs) and 95% confidence intervals (CIs) were used to illustrate the correlation between the joint modifiable risk factor control and the stroke risk. As the degree of risk factor control increased, a gradual reduction in stroke risk was observed. Hypertensive patients who had the optimal risk factor control (≥5 risk factor controls) had a 14.6% lower stroke risk than those who controlled 2 or fewer (HR: 0.854; 95% CI: 804-0.908; p < 0.001). The excess risk of stroke linked to hypertension slowly diminished as the number of controlled risk factors increased. However, the risk was still 25.1% higher for hypertensive patients with optimal risk factor control as compared to the non-hypertensive population (HR: 1.251; 95% CI: 1.100-1.422; p < 0.001). The protective effect of joint risk factor control against the stroke risk due to hypertension was stronger in medicated hypertensive patients than in those not medicated. This finding leads to the conclusion that joint risk factor control combined with pharmacological treatment could potentially eliminate the excess risk of stroke associated with hypertension.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimal blood pressure control with fewer antihypertensive medications: Achieved mostly in low-risk hypertensive patients. 用较少的降压药物达到最佳血压控制效果:主要在低风险高血压患者中实现。
IF 2.7 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-09-28 DOI: 10.1111/jch.14903
Zhanyang Zhou, Huanhuan Miao, Shijie Yang, Zheng Yin, Yingjun Chen, Yuqing Zhang

Recent studies indicate that intensive blood pressure (BP) targets can be reached with less than two medications. This cross-sectional study, involving 4991 individuals from the Majiapu community, assessed the correlation between BP control and the burden of antihypertensive drugs. Participants on medication were categorized into controlled (BP < 140/90 mm Hg) and uncontrolled (BP ≥ 140/90 mm Hg) groups, with the former further divided into optimal (BP < 130/80 mm Hg) and good control (BP < 140/90 but >130/80 mm Hg) subgroups. Multivariate logistic regression analyzed factors affecting hypertension control across these BP categories. The study found that, 54% of participants had hypertension. Of those treated (62.5%), 55.7% achieved BP control, including 23.15% maintaining BP below 130/80 mm Hg. The average number of antihypertensive medications was 1.61 for the controlled group (with an average BP of 126.6/76 mm Hg) and 1.75 for the uncontrolled group (with an average BP of 150.6/84.0 mm Hg). Additionally, the average number of antihypertensive medications was 1.66 in the good control group and 1.55 in the optimal control group. The uncontrolled group had a higher mean systematic coronary risk estimation (SCORE) of 5.59, against 3.97 and 2.5 in the good and optimal control groups, respectively. Key factors linked to poor BP control included age over 65, male sex, obesity, and former smoking, whereas lipid-lowering medication use was associated with better control. In conclusions, patients needing fewer antihypertensive drugs to achieve stricter targets may have a lower risk profile. Notably, only a small proportion of treated patients are low-risk individuals who can easily achieve BP levels below 130/80 mm Hg.

最近的研究表明,只需服用不到两种药物就能达到强化血压(BP)目标。这项横断面研究涉及马家堡社区的 4991 人,评估了血压控制与降压药物负担之间的相关性。接受药物治疗的参与者被分为血压控制(血压 130/80 mm Hg)亚组。多变量逻辑回归分析了这些血压类别中影响高血压控制的因素。研究发现,54% 的参与者患有高血压。在接受治疗的人(62.5%)中,55.7%实现了血压控制,其中23.15%将血压维持在130/80毫米汞柱以下。控制组(平均血压为 126.6/76 mm Hg)和未控制组(平均血压为 150.6/84.0 mm Hg)的平均降压药物服用次数分别为 1.61 次和 1.75 次。此外,良好控制组的平均降压药物数量为 1.66 种,最佳控制组为 1.55 种。未控制组的平均系统冠状动脉风险估计值(SCORE)较高,为 5.59,而良好控制组和最佳控制组分别为 3.97 和 2.5。与血压控制不佳有关的主要因素包括 65 岁以上、男性、肥胖和曾经吸烟,而降脂药物的使用与较好的血压控制有关。结论是,需要使用较少降压药以达到更严格目标的患者可能风险较低。值得注意的是,在接受治疗的患者中,只有一小部分是低风险人群,他们可以轻松将血压控制在 130/80 mm Hg 以下。
{"title":"Optimal blood pressure control with fewer antihypertensive medications: Achieved mostly in low-risk hypertensive patients.","authors":"Zhanyang Zhou, Huanhuan Miao, Shijie Yang, Zheng Yin, Yingjun Chen, Yuqing Zhang","doi":"10.1111/jch.14903","DOIUrl":"https://doi.org/10.1111/jch.14903","url":null,"abstract":"<p><p>Recent studies indicate that intensive blood pressure (BP) targets can be reached with less than two medications. This cross-sectional study, involving 4991 individuals from the Majiapu community, assessed the correlation between BP control and the burden of antihypertensive drugs. Participants on medication were categorized into controlled (BP < 140/90 mm Hg) and uncontrolled (BP ≥ 140/90 mm Hg) groups, with the former further divided into optimal (BP < 130/80 mm Hg) and good control (BP < 140/90 but >130/80 mm Hg) subgroups. Multivariate logistic regression analyzed factors affecting hypertension control across these BP categories. The study found that, 54% of participants had hypertension. Of those treated (62.5%), 55.7% achieved BP control, including 23.15% maintaining BP below 130/80 mm Hg. The average number of antihypertensive medications was 1.61 for the controlled group (with an average BP of 126.6/76 mm Hg) and 1.75 for the uncontrolled group (with an average BP of 150.6/84.0 mm Hg). Additionally, the average number of antihypertensive medications was 1.66 in the good control group and 1.55 in the optimal control group. The uncontrolled group had a higher mean systematic coronary risk estimation (SCORE) of 5.59, against 3.97 and 2.5 in the good and optimal control groups, respectively. Key factors linked to poor BP control included age over 65, male sex, obesity, and former smoking, whereas lipid-lowering medication use was associated with better control. In conclusions, patients needing fewer antihypertensive drugs to achieve stricter targets may have a lower risk profile. Notably, only a small proportion of treated patients are low-risk individuals who can easily achieve BP levels below 130/80 mm Hg.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unattended Office Heart Rate Measurement: A New Challenge in Clinical Practice? 无人值守的办公室心率测量:临床实践的新挑战?
IF 2.7 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-09-26 DOI: 10.1111/jch.14909
Paolo Palatini
{"title":"Unattended Office Heart Rate Measurement: A New Challenge in Clinical Practice?","authors":"Paolo Palatini","doi":"10.1111/jch.14909","DOIUrl":"https://doi.org/10.1111/jch.14909","url":null,"abstract":"","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum N-Terminal Pro-B-Type Natriuretic Peptide Is Associated With Insulin Resistance in Chinese: Danyang Study. 血清 N 端 Pro-B 型钠尿肽与中国人的胰岛素抵抗有关:丹阳研究
IF 2.7 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-09-23 DOI: 10.1111/jch.14906
Ziwen Zheng, Junya Liang, Yun Gao, Mulian Hua, Siqi Zhang, Ming Liu, Zhuyuan Fang

The association of serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) with insulin resistance (IR), as measured by homeostasis model assessment of insulin resistance (HOMA-IR), in the general population is unclear. Our study aimed to characterize its relationship in a large community-based population. Subjects were recruited from the Danyang city between 2017 and 2019. Serum NT-proBNP was measured using an enhanced chemiluminescence immunoassay. IR was defined by a HOMA-IR in the highest sex-specific quartile. Categorical and continuous analyses were performed with sex-specific NT-proBNP tertiles and naturally logarithmically transformed NT-proBNP (lnNTproBNP), respectively. The 2945 participants (mean age 52.8 years) included 1728 (58.7%) women, 1167 (39.6%) hypertensive patients, 269 (9.1%) diabetic patients, and 736 (25.0%) patients with IR. In simple and multivariate-adjusted regression analyses, serum lnNTproBNP were both negatively associated with HOMA-IR (β = -0.19 to -0.25; p < 0.0001). Similar results were also obtained in multiple subgroup analyses. In multiple logistic regression analyses, elevated serum NT-proBNP was associated with lower risks of IR (odds ratios: 0.68 and 0.39; 95% confidence intervals: 0.61-0.74 and 0.30-0.50 for lnNTproBNP and top vs. bottom tertiles, respectively; p < 0.0001). In conclusion, increased serum NT-proBNP level was strongly associated with a lower risk of IR in Chinese.

在普通人群中,血清 N 端前 B 型钠尿肽(NT-proBNP)与胰岛素抵抗(IR)(通过胰岛素抵抗稳态模型评估(HOMA-IR)测量)之间的关系尚不清楚。我们的研究旨在确定其在大型社区人群中的关系。受试者于2017年至2019年期间从丹阳市招募。使用增强化学发光免疫测定法测定血清NT-proBNP。IR的定义是HOMA-IR处于最高性别特异性四分位数。分类分析和连续分析分别采用性别特异性NT-proBNP四分位数和自然对数转换NT-proBNP(lnNTproBNP)进行。2945 名参与者(平均年龄 52.8 岁)中包括 1728 名女性(58.7%)、1167 名高血压患者(39.6%)、269 名糖尿病患者(9.1%)和 736 名红外患者(25.0%)。在简单和多变量调整回归分析中,血清 lnNTproBNP 均与 HOMA-IR 呈负相关(β = -0.19 至 -0.25;P < 0.0001)。在多个亚组分析中也得到了类似的结果。在多重逻辑回归分析中,血清 NT-proBNP 升高与较低的 IR 风险相关(几率:0.68 和 0.39;p < 0.0001):0.68和0.39;95%置信区间:0.61-0.74和0.30-0.50(lnNTproBNP和最高与最低三等分位数);P<0.0001)。总之,血清NT-proBNP水平的升高与中国人较低的红外风险密切相关。
{"title":"Serum N-Terminal Pro-B-Type Natriuretic Peptide Is Associated With Insulin Resistance in Chinese: Danyang Study.","authors":"Ziwen Zheng, Junya Liang, Yun Gao, Mulian Hua, Siqi Zhang, Ming Liu, Zhuyuan Fang","doi":"10.1111/jch.14906","DOIUrl":"https://doi.org/10.1111/jch.14906","url":null,"abstract":"<p><p>The association of serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) with insulin resistance (IR), as measured by homeostasis model assessment of insulin resistance (HOMA-IR), in the general population is unclear. Our study aimed to characterize its relationship in a large community-based population. Subjects were recruited from the Danyang city between 2017 and 2019. Serum NT-proBNP was measured using an enhanced chemiluminescence immunoassay. IR was defined by a HOMA-IR in the highest sex-specific quartile. Categorical and continuous analyses were performed with sex-specific NT-proBNP tertiles and naturally logarithmically transformed NT-proBNP (lnNTproBNP), respectively. The 2945 participants (mean age 52.8 years) included 1728 (58.7%) women, 1167 (39.6%) hypertensive patients, 269 (9.1%) diabetic patients, and 736 (25.0%) patients with IR. In simple and multivariate-adjusted regression analyses, serum lnNTproBNP were both negatively associated with HOMA-IR (β = -0.19 to -0.25; p < 0.0001). Similar results were also obtained in multiple subgroup analyses. In multiple logistic regression analyses, elevated serum NT-proBNP was associated with lower risks of IR (odds ratios: 0.68 and 0.39; 95% confidence intervals: 0.61-0.74 and 0.30-0.50 for lnNTproBNP and top vs. bottom tertiles, respectively; p < 0.0001). In conclusion, increased serum NT-proBNP level was strongly associated with a lower risk of IR in Chinese.</p>","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142299900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between fibrosis‐4 index and cognitive impairment in elderly patients with hypertension: A cross‐sectional study 老年高血压患者的纤维化-4 指数与认知障碍之间的关系:横断面研究
IF 2.8 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-09-14 DOI: 10.1111/jch.14890
Hong Ding, Jingtao Wang, Shu Liu, Yafei Xie, Xiaowei Zhang, Jing Yu
The fibrosis‐4 index (FIB‐4) is a noninvasive fibrosis test that is recommended for patients who are at risk of developing hepatic fibrosis. The aim of the study was to explore the correlation between FIB‐4 index and the decline of cognitive function among older patients with hypertension. The study used a cross‐sectional design to analyze data obtained from the NHANES 2011–2014. The significance of the FIB‐4 index correlation with cognitive function in individuals over the age of 60 was evaluated via multivariate regression models. The nonlinear link was described and fitted smoothed curves. There were a total of 2039 participants in the study, and those with a higher FIB‐4 index were more susceptible to developing cognitive decline. In the completely adjusted model, the association remained statistically significant between the FIB‐4 index and poor cognitive function as measured by CERAD: Total Score (OR = 0.72, 0.57−0.91), Animal Fluency Score (OR = 0.66, 0.48−0.91), and Digit Symbol Score (OR = 0.36, 0.17−0.77). A nonlinear association was found between the FIB‐4 and poor cognitive ability: Total Score, CERAD: Score Delayed Recall, Digit Symbol Score, and Animal Fluency Score. In elderly patients with hypertension, a high FIB‐4 index is correlated with an increased prevalence of cognitive decline. Hence, the FIB‐4 index could potentially serve as a valuable tool for determining individuals with hypertension who are susceptible to both liver‐related complications and cognitive impairment.
肝纤维化-4指数(FIB-4)是一种无创肝纤维化检测方法,推荐用于有肝纤维化风险的患者。本研究旨在探讨 FIB-4 指数与老年高血压患者认知功能下降之间的相关性。研究采用横断面设计,分析了从 2011-2014 年国家健康调查(NHANES)中获得的数据。通过多变量回归模型评估了 FIB-4 指数与 60 岁以上人群认知功能相关性的意义。对非线性联系进行了描述,并拟合了平滑曲线。该研究共有 2039 名参与者,FIB-4 指数越高的人越容易出现认知功能衰退。在完全调整模型中,FIB-4指数与CERAD测量的认知功能低下之间的关系仍具有统计学意义:总分(OR = 0.72,0.57-0.91)、动物流畅度得分(OR = 0.66,0.48-0.91)和数字符号得分(OR = 0.36,0.17-0.77)。FIB-4 与认知能力差之间存在非线性关联:总分、CERAD:得分延迟回忆、数字符号得分和动物流畅性得分。在老年高血压患者中,FIB-4 指数高与认知能力下降的发生率增加相关。因此,FIB-4指数有可能成为一种有价值的工具,用于确定哪些高血压患者容易出现肝脏相关并发症和认知障碍。
{"title":"Association between fibrosis‐4 index and cognitive impairment in elderly patients with hypertension: A cross‐sectional study","authors":"Hong Ding, Jingtao Wang, Shu Liu, Yafei Xie, Xiaowei Zhang, Jing Yu","doi":"10.1111/jch.14890","DOIUrl":"https://doi.org/10.1111/jch.14890","url":null,"abstract":"The fibrosis‐4 index (FIB‐4) is a noninvasive fibrosis test that is recommended for patients who are at risk of developing hepatic fibrosis. The aim of the study was to explore the correlation between FIB‐4 index and the decline of cognitive function among older patients with hypertension. The study used a cross‐sectional design to analyze data obtained from the NHANES 2011–2014. The significance of the FIB‐4 index correlation with cognitive function in individuals over the age of 60 was evaluated via multivariate regression models. The nonlinear link was described and fitted smoothed curves. There were a total of 2039 participants in the study, and those with a higher FIB‐4 index were more susceptible to developing cognitive decline. In the completely adjusted model, the association remained statistically significant between the FIB‐4 index and poor cognitive function as measured by CERAD: Total Score (OR = 0.72, 0.57−0.91), Animal Fluency Score (OR = 0.66, 0.48−0.91), and Digit Symbol Score (OR = 0.36, 0.17−0.77). A nonlinear association was found between the FIB‐4 and poor cognitive ability: Total Score, CERAD: Score Delayed Recall, Digit Symbol Score, and Animal Fluency Score. In elderly patients with hypertension, a high FIB‐4 index is correlated with an increased prevalence of cognitive decline. Hence, the FIB‐4 index could potentially serve as a valuable tool for determining individuals with hypertension who are susceptible to both liver‐related complications and cognitive impairment.","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142254111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lipoprotein(a) among normotensive patients and risk of incident hypertension 正常血压患者的脂蛋白(a)与高血压发病风险
IF 2.8 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-09-14 DOI: 10.1111/jch.14904
Alexander R. Zheutlin, Joshua A. Jacobs, Brian Stamm, Regina Royan
Lipoprotein(a) has been shown to be disruptive to local endothelial cells, whose integrity is critical to blood pressure (BP) regulation. Cross‐sectional analysis has shown an association between lipoprotein(a) and prevalent hypertension, though it is unclear if lipoprotein(a) increases risk of incident hypertension. To assess this, the authors measured baseline lipoprotein(a) among 5307 normotensive patients (median age 26 years (interquartile range [IQR] 12–50) and used Cox proportional hazard models to generate hazard rations (HR) with 95% confidence intervals (CI; median follow‐up 10‐years). The authors categorized lipoprotein(a) as <15 mg/dL, 15–<30 mg/dL, 30–50 mg/dL, >50 mg/dL, and performed subgroup analysis of adults >50 years at baseline. Incident hypertension was defined as a measured BP ≥140/90 mm Hg or a new ICD‐9/10 code. After adjustment, hypertension for patients with baseline lipoprotein(a) 15–<30 mg/dL, 30–50 mg/dL, and >50 mg/dL was 0.91 (0.72–1.16), 1.05 (0.79–1.38), and 1.02 (0.83–1.26; vs. <15 mg/dL). However, among adults >50 years, lipoprotein(a) >50 mg/dL was associated with increased incident hypertension (1.62 [1.17–2.26]).
脂蛋白(a)已被证明会破坏局部内皮细胞,而内皮细胞的完整性对血压(BP)调节至关重要。横断面分析表明,脂蛋白(a)与流行性高血压之间存在关联,但目前尚不清楚脂蛋白(a)是否会增加高血压的发病风险。为了评估这一点,作者测量了 5307 名正常血压患者(中位数年龄为 26 岁(四分位数间距 [IQR] 12-50))的基线脂蛋白(a),并使用 Cox 比例危险模型得出危险系数(HR)及 95% 置信区间(CI;中位数随访 10 年)。作者将脂蛋白(a)分为15毫克/分升、15-30毫克/分升、30-50毫克/分升和50毫克/分升,并对基线年龄为50岁的成年人进行了亚组分析。新发高血压的定义是测量血压≥140/90 mm Hg 或有新的 ICD-9/10 编码。经过调整后,基线脂蛋白(a)为 15<30 mg/dL、30-50 mg/dL 和 >50 mg/dL 的高血压患者的血压分别为 0.91(0.72-1.16)、1.05(0.79-1.38)和 1.02(0.83-1.26;对比<15 mg/dL)。然而,在 50 岁的成年人中,脂蛋白(a)50 毫克/分升与高血压发病率增加有关(1.62 [1.17-2.26])。
{"title":"Lipoprotein(a) among normotensive patients and risk of incident hypertension","authors":"Alexander R. Zheutlin, Joshua A. Jacobs, Brian Stamm, Regina Royan","doi":"10.1111/jch.14904","DOIUrl":"https://doi.org/10.1111/jch.14904","url":null,"abstract":"Lipoprotein(a) has been shown to be disruptive to local endothelial cells, whose integrity is critical to blood pressure (BP) regulation. Cross‐sectional analysis has shown an association between lipoprotein(a) and prevalent hypertension, though it is unclear if lipoprotein(a) increases risk of incident hypertension. To assess this, the authors measured baseline lipoprotein(a) among 5307 normotensive patients (median age 26 years (interquartile range [IQR] 12–50) and used Cox proportional hazard models to generate hazard rations (HR) with 95% confidence intervals (CI; median follow‐up 10‐years). The authors categorized lipoprotein(a) as &lt;15 mg/dL, 15–&lt;30 mg/dL, 30–50 mg/dL, &gt;50 mg/dL, and performed subgroup analysis of adults &gt;50 years at baseline. Incident hypertension was defined as a measured BP ≥140/90 mm Hg or a new ICD‐9/10 code. After adjustment, hypertension for patients with baseline lipoprotein(a) 15–&lt;30 mg/dL, 30–50 mg/dL, and &gt;50 mg/dL was 0.91 (0.72–1.16), 1.05 (0.79–1.38), and 1.02 (0.83–1.26; vs. &lt;15 mg/dL). However, among adults &gt;50 years, lipoprotein(a) &gt;50 mg/dL was associated with increased incident hypertension (1.62 [1.17–2.26]).","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142268981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hemodynamic phenotypes in chronic kidney disease patients based on linear regression of blood pressure parameters 基于血压参数线性回归的慢性肾病患者血液动力学表型
IF 2.8 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-09-14 DOI: 10.1111/jch.14880
Katarzyna Cierpka‐Kmieć, Raissa Khursa, Dagmara Hering
Classic and non‐classic cardiovascular (CV) risk factors accumulate in chronic kidney disease (CKD), contributing to vascular remodeling and hemodynamic abnormalities. This study aimed to determine hemodynamic phenotypes based on linear regression of blood pressure (BP) parameters in stage G3‐G4 CKD patients at very high CV risk. 24‐h ambulatory BP monitoring (ABPM), carotid‐femoral pulse wave velocity (PWV) and central BP were obtained from 52 patients (aged 60 ± 11 years, BMI 30 ± 6 kg/m2) with stage G3‐G4 CKD (eGFR 44 ± 12 mL/min./1.73 m2). Linear BP regression coefficients were generated to determine hemodynamic phenotypes using ABPM data. Coexisting hypertension was present in 45 (86%) patients, out of whom 33 (73%) had BP controlled. 24‐h mean systolic/diastolic BP was 128 ± 18/75 ± 12 mm Hg. Twenty‐six patients demonstrated the harmonious (H) and 26 patients diastolic dysfunctional (D) hemodynamic phenotypes. eGFR was not significantly different between both phenotypes. Compared to phenotype H, patients with phenotype D were older (57 ± 11 vs. 63 ± 10 years, p = .04), had higher PWV (8.2 [7.3–10.3] vs. 9.7 [8.3–10.9] m/s, p = .02), ambulatory arterial stiffness index (AASI) (0.31 ± 0.1 vs. 0.40 ± 0.1, p = .02), systolic BP (128 [122–130] vs. 137 [130–150] mm Hg, p = .001) and systolic BP variability (BPV) (11.7 ± 2.3 vs. 15.7 ± 3.4 mm Hg, p < .0001). Our findings suggest that one in two patients with stage G3‐G4 CKD demonstrates an unfavorable D hemodynamic phenotype based on a linear regression model, associated with higher PWV, AASI, systolic BP, and systolic BPV. Further studies are required to assess the clinical utility of hemodynamic phenotypes and whether the D phenotype may predict latent circulatory disorders and outcomes.
慢性肾脏病(CKD)中的经典和非经典心血管(CV)风险因素不断累积,导致血管重塑和血液动力学异常。本研究旨在根据血压(BP)参数的线性回归,确定G3-G4期CKD高危患者的血液动力学表型。研究人员采集了 52 名 G3-G4 期 CKD 患者(年龄 60 ± 11 岁,体重指数 30 ± 6 kg/m2)(eGFR 44 ± 12 mL/min./1.73 m2)的 24 小时动态血压监测(ABPM)、颈动脉-股动脉脉搏波速度(PWV)和中心血压。利用 ABPM 数据生成线性血压回归系数,以确定血液动力学表型。45例(86%)患者合并高血压,其中33例(73%)血压得到控制。24 小时平均收缩压/舒张压分别为 128 ± 18/75 ± 12 mm Hg。26 名患者表现为和谐型(H)血液动力学表型,26 名患者表现为舒张功能障碍型(D)血液动力学表型。与表型 H 相比,表型 D 患者年龄更大(57 ± 11 岁 vs. 63 ± 10 岁,p = .04),脉搏波速度更高(8.2 [7.3-10.3] m/s vs. 9.7 [8.3-10.9] m/s,p = .02),动态动脉僵化指数(AASI)更高(0.31 ± 0.1 vs. 0.40 ± 0.1,p = .02)、收缩压(128 [122-130] vs. 137 [130-150] mm Hg,p = .001)和收缩压变异性(BPV)(11.7 ± 2.3 vs. 15.7 ± 3.4 mm Hg,p <.0001)。我们的研究结果表明,根据线性回归模型,每两名 G3-G4 期 CKD 患者中就有一人表现出不利的 D 型血液动力学表型,与较高的脉搏波速度、AASI、收缩压和收缩压变异性相关。还需要进一步的研究来评估血液动力学表型的临床实用性,以及 D 表型是否可以预测潜在的循环系统疾病和预后。
{"title":"Hemodynamic phenotypes in chronic kidney disease patients based on linear regression of blood pressure parameters","authors":"Katarzyna Cierpka‐Kmieć, Raissa Khursa, Dagmara Hering","doi":"10.1111/jch.14880","DOIUrl":"https://doi.org/10.1111/jch.14880","url":null,"abstract":"Classic and non‐classic cardiovascular (CV) risk factors accumulate in chronic kidney disease (CKD), contributing to vascular remodeling and hemodynamic abnormalities. This study aimed to determine hemodynamic phenotypes based on linear regression of blood pressure (BP) parameters in stage G3‐G4 CKD patients at very high CV risk. 24‐h ambulatory BP monitoring (ABPM), carotid‐femoral pulse wave velocity (PWV) and central BP were obtained from 52 patients (aged 60 ± 11 years, BMI 30 ± 6 kg/m<jats:sup>2</jats:sup>) with stage G3‐G4 CKD (eGFR 44 ± 12 mL/min./1.73 m<jats:sup>2</jats:sup>). Linear BP regression coefficients were generated to determine hemodynamic phenotypes using ABPM data. Coexisting hypertension was present in 45 (86%) patients, out of whom 33 (73%) had BP controlled. 24‐h mean systolic/diastolic BP was 128 ± 18/75 ± 12 mm Hg. Twenty‐six patients demonstrated the harmonious (H) and 26 patients diastolic dysfunctional (D) hemodynamic phenotypes. eGFR was not significantly different between both phenotypes. Compared to phenotype H, patients with phenotype D were older (57 ± 11 vs. 63 ± 10 years, <jats:italic>p</jats:italic> = .04), had higher PWV (8.2 [7.3–10.3] vs. 9.7 [8.3–10.9] m/s, <jats:italic>p</jats:italic> = .02), ambulatory arterial stiffness index (AASI) (0.31 ± 0.1 vs. 0.40 ± 0.1, <jats:italic>p</jats:italic> = .02), systolic BP (128 [122–130] vs. 137 [130–150] mm Hg, <jats:italic>p</jats:italic> = .001) and systolic BP variability (BPV) (11.7 ± 2.3 vs. 15.7 ± 3.4 mm Hg, <jats:italic>p</jats:italic> &lt; .0001). Our findings suggest that one in two patients with stage G3‐G4 CKD demonstrates an unfavorable D hemodynamic phenotype based on a linear regression model, associated with higher PWV, AASI, systolic BP, and systolic BPV. Further studies are required to assess the clinical utility of hemodynamic phenotypes and whether the D phenotype may predict latent circulatory disorders and outcomes.","PeriodicalId":50237,"journal":{"name":"Journal of Clinical Hypertension","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142254112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Clinical Hypertension
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1